Literature DB >> 18321153

Emerging drugs in the treatment of advanced gastric cancer.

Eric D Tetzlaff1, Putao Cen, Jaffer A Ajani.   

Abstract

BACKGROUND: Gastroesopheal cancer is one of the most common cancers worldwide. If detected early, curative treatment is possible. Often, gastroesophageal cancer is detected at an advanced stage when therapy is palliative.
OBJECTIVES: To provide a critical evaluation of historic and recently developed chemotherapy regimens for the treatment of advanced gastroesophageal cancer (AGC).
METHODS: Published clinical trials in AGC as well as selected abstracts presented at international oncology meetings were selected. RESULTS/
CONCLUSION: Chemotherapy has demonstrated a benefit over best supportive care alone by improving the quality and quantity of life for patients with advanced disease. Recent Phase III trials investigating cytotoxic chemotherapy and Phase II trials incorporating biotherapy for the treatment of AGC show promise for the future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321153     DOI: 10.1517/14728214.13.1.135

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  3 in total

Review 1.  Docetaxel: its role in current and future treatments for advanced gastric cancer.

Authors:  Masahiko Nishiyama; Satoru Wada
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

2.  Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.

Authors:  H K Kim; I J Choi; C G Kim; H S Kim; A Oshima; Y Yamada; T Arao; K Nishio; A Michalowski; J E Green
Journal:  Pharmacogenomics J       Date:  2010-12-21       Impact factor: 3.550

3.  Review of docetaxel in the treatment of gastric cancer.

Authors:  Eric D Tetzlaff; Jonathan D Cheng; Jaffer A Ajani
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.